Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 2INTERVENTIONAL

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigilimab in participants with SCD. Participants will be treated for 64 weeks: for 12 weeks in the dose escalation period, where the dose will be escalated to each participant's individual MTD; and for 52 weeks at the MTD in the maintenance period.

Who May Be Eligible (Plain English)

Who May Qualify: - • Adults aged greater than or equal to (\>=) 18 years on the day of signing the willing to sign a consent form form. - • Confirmed diagnosis of SCD of any genotype. - • Experienced 1 to 12 VOCs requiring a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug within the 12 months before Screening. - • HU Regimen: - a. On stable and well-tolerated Hydroxyurea (HU) regimen for at least 30 days before Screening. - or - b. HU was discontinued or refused (eg, due to concern of side effects or lack of effect). Who Should NOT Join This Trial: - • Absolute neutrophil count less than (\<) 2.5 ×10\^9 cells/Litre at Screening or Baseline (Week 1 Day 1). - • If on SCD preventive medication, dose is not stable in the 30 days before Screening. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * • Adults aged greater than or equal to (\>=) 18 years on the day of signing the informed consent form. * • Confirmed diagnosis of SCD of any genotype. * • Experienced 1 to 12 VOCs requiring a visit to a medical facility and treatment with parenteral opioids or a parenteral nonsteroidal anti-inflammatory drug within the 12 months before Screening. * • HU Regimen: * a. On stable and well-tolerated Hydroxyurea (HU) regimen for at least 30 days before Screening. * or * b. HU was discontinued or refused (eg, due to concern of side effects or lack of effect). Exclusion Criteria: * • Absolute neutrophil count less than (\<) 2.5 ×10\^9 cells/Litre at Screening or Baseline (Week 1 Day 1). * • If on SCD preventive medication, dose is not stable in the 30 days before Screening.

Treatments Being Tested

BIOLOGICAL

Anumigilimab

Participants will receive anumigilimab, escalated to a maximum dose guided by absolute neutrophil count (ANC) and safety concerns.

DRUG

Placebo

Volume matched saline will be administered SC.

Locations (3)

The Foundation for Sickle Cell Disease
Hollywood, Florida, United States
Southern Specialty Research
Flowood, Mississippi, United States
Jacobi Medical Center
The Bronx, New York, United States